PDCD1 and non-small cell lung carcinoma: Multivariate analysis confirmed that heightened NLR following treatment served as an independent prognostic indicator for OS (P = 0.003), indicating the potential of NLR six weeks after initiation of anti-PD-1 immunotherapy as a promising prognostic factor for patients with advanced NSCLC.